It follows a similar decision last week by drug discovery company C4X Discovery, which also said it was finding it hard to raise funds on the London Stock Exchange’s junior market. The decisions ...

C4X Discovery has been developing potential oral IL-17 inhibitor drug, which could be used to treat autoimmune diseases including psoriasis, psoriatic arthritis and ankylosing spondylitis.